13.08

1.24% 0.16

After Hours: 12.55 -0.53 -4.05%

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $13.08, with a volume of 1.46M. It is up +1.24% in the last 24 hours and up +19.56% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$12.92

Open:

$12.7

24h Volume:

1.46M

Relative Volume:

0.91

Market Cap:

$1.68B

Revenue:

Net Income/Loss:

$-45.86M

P/E Ratio:

-35.23

EPS:

-0.3713

Net Cash Flow:

$-44.02M

1W Performance:

+13.54%

1M Performance:

+19.56%

6M Performance:

+86.59%

1Y Performance:

+197.95%

1-Day Range:

$12.66

$13.23

1-Week Range:

$11.30

$13.51

52-Week Range:

$4.24

$14.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	13.08	1.66B	0	-45.86M	-44.02M	-0.3713
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

Mar 03, 2026

Value Recap: Can Trevi Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn

Mar 03, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Mar 03, 2026

Mar 02, 2026

Trevi Therapeutics, Inc. Senior Management to Present at 2026 Healthcare Conferences - Quiver Quantitative

Mar 02, 2026

Chronic cough treatment talks: Trevi execs head to Miami and Philly in March - Stock Titan

Mar 02, 2026

MAI Capital Management Cuts Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Mar 02, 2026

Feb 28, 2026

Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio - Yahoo Finance

Feb 28, 2026

TRVI Should I Buy - Intellectia AI

Feb 28, 2026

TRVI PE Ratio & Valuation, Is TRVI Overvalued - Intellectia AI

Feb 28, 2026

Feb 27, 2026